MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2024 International Congress

    Clonazepam as First-Line Therapy for Post-Hypoxic Chorea: A Case Report and Discussion

    G. Chu, R. Koshy, A. Maleki (moreno valley, USA)

    Objective: Reporting a rare case of generalized chorea in a 35-year-old female following cardiac arrest, which demonstrated rapid improvement with a short course of clonazepam.…
  • 2024 International Congress

    Somnolence-Related Events Over Time with Valbenazine Treatment for Chorea Associated with Huntington’s Disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, R. Mehanna, S. Hinton, O. Klepitskaya, H. Zhang, S. Karpuram, D. Thai-Cuarto, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To present somnolence-related events over time from 2 studies of once-daily valbenazine, which is approved for chorea in adults with Huntington’s disease: KINECT®-HD (K-HD,…
  • 2024 International Congress

    Validation of the Korean Version of the Huntington’s Disease Quality of Life Battery for Carers

    HJ. Chang, ES. Oh, WT. Yoon, CY. Lee, JY. Lee (Daejeon, Republic of Korea)

    Objective: This study aimed to develop a Korean version of the Huntington's disease (HD) quality of life battery for carers (K-HDQoL-C) to assess disease-related burden…
  • 2024 International Congress

    Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial

    R. Wells, L. Neilson, A. Mchill, A. Hiller (Portland, USA)

    Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…
  • 2024 International Congress

    Physical Activity Levels and Demographic Characteristics in Individuals with Huntington’s Disease: Insights from the ENROLL-HD Database in an Argentinian Movement Disorder Center

    M. Espindola, N. Gonzalez Rojas, G. da Prat, M. Cesarini, G. Peker, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

    Objective: To assess PA levels in individuals enrolled in the ENROLL-HD database, and compare demographic characteristics between PE practitioners, and non-practitioners Background: Neurological disorders have been…
  • 2024 International Congress

    Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, R. Mehanna, S. Hinton, O. Klepitskaya, H. Zhang, E. Dunayevich, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To present interim analyses from KINECT®-HD2 (NCT04400331), an ongoing open-label study of once-daily valbenazine (VBZ) for chorea associated with Huntington’s disease (HD). Background: In…
  • 2024 International Congress

    Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data

    R. Mehanna, R. Hauser, E. Furr Stimming, L. Citrome, E. Kayson, J. Goldstein, O. Klepitskaya, S. Hinton, H. Zhang, E. Dunayevich, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To assess the treatment effect size of once-daily valbenazine for tardive dyskinesia (TD) and for chorea associated with Huntington’s disease (HD) using data from…
  • 2024 International Congress

    ​​Deciphering the Huntington’s Disease Research Landscape: A Comprehensive Bibliometric and Trend Analysis

    S. Khankar, T. Lalotra, A. Subhedar, S. Joshi, S. Mast, A. Bhonsale (Nagpur, India)

    Objective: To map the Huntington's Disease research landscape, identifying key trends, gaps, and the most impactful studies to guide future research directions and therapeutic strategies.…
  • 2024 International Congress

    Mapping the Efficacy Landscape: A Network Meta-Analysis of Pharmacological Interventions in Huntington’s Disease

    A. Bhonsale, V. Suresh, B. Javed, M. Shamim, T. Dave, V. Ghosh, S. Sen, M. Muneer, D. Dey, M. Jayan, B. Dhakal, S. Vasipalli, R. Jena (Nagpur, India)

    Objective: To evaluate and compare the efficacy of pharmacological interventions for Huntington's Disease through a network meta-analysis, identifying the most effective treatments. Background: Huntington’s Disease…
  • 2024 International Congress

    Huntington’s Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies

    M. Mistry, J. Pace, E. Guivatchian, J. Hinman (Fort Worth, USA)

    Objective: This paper outlines current therapeutic options for HD, and ultimately suggests taking a combinatorial therapeutic approach to slow HD progression by simultaneously treating multiple…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley